Prior to co-founding Beryllium in 2009 I co-founded Pod Holding Ltd (Pod Investment) in 2000 and served as its Managing Partner until 2008. During my 8 years at Pod I served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals and the anti-infectives company Paratek Pharmaceuticals (PRTK)…Read More
I started working at MediChem Life Sciences, a drug discovery and technology company, in a finance role when I graduated from college. deCODE Genetics acquired MediChem three years later, and I stayed on as vice president of finance at the Icelandic company’s U.S. office. Later, I became chief financial officer of Emerald Bio when the company spun out from deCODE in 2009…Read More
As head of research, I utilize my expertise from my time in academia, big pharma, biotech startups and my own consulting firm to lay the groundwork for our company’s future drug discovery methods and breakthroughs. Before joining Beryllium, I founded ALN Associates, a life sciences consultancy…Read More
With over a decade of industry expertise, I have been at the forefront of numerous, successful structure determination research collaborations, including hepatitis C virus (HCV), oncology and diabetes targets. Prior to joining Beryllium, I was a crystallographer and senior research scientist at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)…Read More
I began my career in the biotech industry in 1995 and it has included positions at Thermo Fisher and Lonza Biologics. I earned my Bachelor’s degree from Old Dominion University. As a Navy spouse I had the opportunity to live all over the world from Italy to Hawaii to Washington State…Read More
Justin Boyd, Ph.D.
I bring to Beryllium over a decade of research experience in phenotypic profiling, especially in neurobiology. As an entrepreneurial scientist, I am accomplished in the fields of neuroscience, stem cell biology, and drug discovery. The challenge that I hope to address is creating innovation and improved efficiency in drug discovery…Read More
Doug Davies, Ph.D.
I have been working with an interdisciplinary team to build and strengthen fragment-based discovery at Beryllium for ten years. I worked as the project lead on the effort to build our first in-house fragment screening collection, the metabolome-influenced “Fragments of Life.” …Read More